Metastatic Castration-Resistant Prostate Cancer Articles

Bipolar Androgen Therapy Effective After Enzalutamide in mCRPC
One-third of asymptomatic men with metastatic castration-resistant prostate cancer who progressed on enzalutamide (Xtandi) achieved a 50% decline in PSA concentration from baseline (PSA50) following bipolar androgen therapy.
Second-Line Docetaxel Superior to ARATA in mCRPC
Men with metastatic castration-resistant prostate cancer who progressed following initial treatment with an androgen receptor-axis-targeted agent had better survival when treated with docetaxel in second-line.
Role of PARP Inhibitors Developing in mCRPC
Alicia Morgan, MD, discusses the role of PARP inhibitors as a novel treatment strategy for patients with metastatic castration-resistant prostate cancer.
Immunotherapy Continues Growth With Trials in mCRPC
Julie Graff, MD, comments on the state of immunotherapy in mCRPC and some ongoing research in the field.
Radium-223 Well Tolerated in Long-Term Safety Results in mCRPC
Three-year safety results from the ALSYMPCA trial showed that treatment with radium-223 dichloride (Xofigo) for men with mCRPC and symptomatic bone metastases was associated with minimal nonhematologic AEs.
Radium-223/Abiraterone Phase III mCRPC Trial Unblinded
The phase III ERA223 trial exploring radium-223 dichloride plus abiraterone acetate in patients with asymptomatic or mildly symptomatic chemotherapy-naïve metastatic castration-resistant prostate cancer has been unblinded early.
Radium-223 Retreatment Shows Promise in mCRPC
A second course of radium-223 was associated with minimal hematologic toxicity and low radiographic bone progression rates in a phase I/II study of men with metastatic castration-resistant prostate cancer.
Challenges in mCRPC Landscape Surround Sequencing, Biomarkers, and PARP Inhibition
Tanya B. Dorff, MD, discusses several important components regarding metastatic castration-resistant prostate cancer treatment, including the addition of novel drugs, optimal therapeutic sequences, and the identification of predictive biomarkers.
LDH a Predictor for OS in mCRPC Following Radium-223
Log LDH was the strongest predictor for overall survival with radium-223 for men with metastatic castration resistant prostate cancer.
PARP Inhibitor Tested in mCRPC
Rucaparib, a drug approved for the treatment of ovarian cancer, might also be used to treat patients with metastatic castration-resistant prostate cancer.
Publication Bottom Border
Border Publication